Objective: To evaluate the efficacy and safety of anti-Interleukin-5 therapy in patients with asthma. Methods: Data were collected from PubMed, E-Mbase, Springer, Ovid, Cochrane Library, ClinicalTrials.gov, CNKI and Wanfang database (-Feb 2017). Bibliographies of the retrieved articles were checked and analyzed. Results: Twenty publications involving a total of 6 406 patients were used in the analysis, including 23 randomly controlled trials (RCTs) which compared anti-interleukin 5 monoclonal antibody with placebo. Pooled analyses showed that anti-interleukin 5 monoclonal antibody significantly reduced exacerbation risk [RR=0.66, 95%CI(0.59, 0.73)], increased FEV(1)[MD=0.10, 95%CI(0.07, 0.13)] and FEV(1)% predicted [MD=3.90, 95%CI(1.86, 5.95)], and improved the scores on the Asthma Quality of Life Questionnaire (AQLQ) [MD=0.24, 95%CI(0.16, 0.32)]. Anti-interleukin 5 monoclonal antibody was also associated with significantly decreased risk of adverse events than placebo[OR=0.71, 95%CI(0.58, 0.87)]. Conclusion: Anti-interleukin 5 monoclonal antibody reduces the risk of exacerbations and improves quality of life in patients with asthma, and is tolerated well.
目的： 系统评价抗IL－5抗体治疗支气管哮喘(哮喘)患者的疗效及安全性。 方法： 根据特定中英文检索词检索PubMed、EMbase、Springer、Ovid、Cochrane Library、ClinicalTrials.gov和CNKI、万方数据库的所有相关临床随机对照研究(RCT)，检索时间截至2017年2月。同时检索纳入文献的参考文献，并逐个进行质量评价和资料提取。采用RevMan5.3软件进行统计学分析。 结果： 共纳入20篇文献，23个RCT，共计6 406例患者。荟萃分析结果显示，抗IL－5抗体可明显降低哮喘急性加重的发生率[RR＝0.66，95%CI(0.59，0.73)]，改善患者FEV(1)[MD＝0.10，95%CI(0.07，0.13)]、FEV(1)占预计值% [MD＝3.90，95%CI(1.86，5.95)]和哮喘生命质量问卷(AQLQ)评分[MD＝0.24，95%CI(0.16，0.32)]，且降低了不良事件的发生风险[OR＝0.71，95%CI(0.58，0.87)]。 结论： 抗IL－5抗体可降低哮喘患者急性加重的发生率，并改善患者肺功能及生命质量，且具有较好的耐受性。.
Keywords: Antibodies; Asthma; Interleukin-5; Meta analysis.